Expert view: Delivering better therapeutics: fully characterising and recovering T cells
Posted: 1 June 2020 | Berkeley Lights | No comments yet
T cell-based therapies have shown promise as new treatment options for various cancers.
However, the functional heterogeneity of T cells can prove challenging during their development into therapeutics. These therapies have been associated with side effects relating to cytokine release syndrome (CRS) and neurotoxicity, placing extra importance on the understanding of functions such as cytokine release and killing kinetics at the single-cell level.
Related topics
Immunotherapy, Therapeutics
Related organisations
Berkeley Lights